Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Li, Zhaohui; Zhang, Zengyuan; Rosen, Steven T.; Feng, Mingye

doi:10.1016/j.cellin.2024.100150

Cell Insight

2024

DOI: 10.1016/j.cellin.2024.100150

|View full text |Cite

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Zhaohui Li,

Zengyuan Zhang,

Steven T. Rosen

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Radić,

Offersgaard,

Kadavá

et al. 2024

Preprint

View full text Add to dashboard Cite

Hepatitis C virus (HCV) currently causes about one million infections and 240,000 deaths worldwide each year. To reach the goal set by the World Health Organization (WHO) of global HCV elimination by 2030, it is critical to develop a prophylactic vaccine. Broadly neutralizing antibodies (bNAbs) target the E1E2 envelope glycoproteins on the viral surface, can neutralize a broad range of the highly diverse circulating HCV strains and are essential tools to inform vaccine design. However, bNAbs targeting a single E1E2 epitope might be limited in neutralization breadth, which can be enhanced by using combinations of bNAbs that target different envelope epitopes. We have generated 60 IgG-like bispecific antibodies (bsAbs) that can simultaneously target two distinct epitopes on E1E2. We combine non-overlapping E1E2 specificities into three types of bsAbs, each containing a different hinge length. The bsAbs show retained or increased potency and breadth against a diverse panel of HCV pseudoparticles (HCVpp) and HCV produced in cell culture (HCVcc) compared to monospecific and cocktail controls. Additionally, we demonstrate that changes in the hinge length of bsAbs can alter the binding stoichiometry to E1E2. These results provide insights into the binding modes and the role of avidity in bivalent targeting of diverse E1E2 epitopes, and suggest structural differences between HCVpp and HCVcc. This study illustrates how potential cooperative effects of HCV bNAbs can be utilized by strategically designing bispecific constructs. These new HCV bsAbs can guide vaccine development and unlock novel therapeutic and prophylactic strategies against HCV and other (flavi)viruses.

show abstract

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Radić,

Offersgaard,

Kadavá

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Cited by 1 publication

References 76 publications

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Contact Info

Product

Resources

About